若不治疗耐多药结核病的危险。
The risk of leaving multidrug-resistant tuberculosis untreated.
他们要知道，治疗耐多药结核病费用极其昂贵，因此，他们要从绿灯委员会那里寻求援助，确保二线药物供应。
They have to know that treating MDR-TB can be very, very expensive – so they have to look for help from the Green Light Committee in securing the second-line drugs.
到2005年，绿灯委员会行动已积累了足够的证据，为制定在贫困环境中治疗耐多药结核病的新世卫组织政策铺平了道路。
By 2005, the Green Light Committee Initiative had accumulated enough evidence to pave the way for a new WHO policy on treating MDR-TB in poor Settings.
管理和治疗耐多药结核病从不是件简单的事，即便在最先进的医疗环境下也是如此，结核病治疗规划还需应对一些复杂情况。
Managing and treating MDR-TB are never simple, not even in the most advanced medical settings, and the programme has wrestled with several complications.
控制耐多药结核病的努力特别容易受到这类压力的影响，因为需要高水平的人力资源来有效诊断和治疗患者。
Efforts to control MDR-TB are particularly vulnerable to such pressures because of the high level of human resources needed to diagnose and treat patients effectively.
控制失效导致耐多药结核病病例上升，而此类结核病的治疗要困难许多，也昂贵许多。这提醒我们要时刻牢记挫折风险。
Lapses in control drive the rise of multidrug-resistant TB, which is far more costly and difficult to treat, and remind us of the constant risk of setbacks.
对普通结核病的不规范治疗致使耐多药菌株滋生繁殖。
Substandard treatment of normal TB drives the development of multi-drug resistant strains.
用于疗耐多药结核病漫长治疗的药品费用比治疗常见结核病菌株的药品可能贵100倍以上。
The drugs for the lengthy treatment of MDR-TB can cost more than 100 times that of the drugs to treat common tuberculosis strains.
全球范围内，接受治疗的病人当中，有60%报告治愈，但耐多药结核病病人中，只有大约7%得以确诊。
Worldwide, of those patients receiving treatment, 60% were reported as cured. However, only an estimated 7% of all MDR-TB patients are diagnosed.
实在吃了一惊，我连什么是结核病都不知道，几个月后又被诊断为耐多药结核病，我更害怕了，我不知道能不能得到治疗。
And then when I was diagnosed with MDR-TB several months later, I was even more scared. I didn't know if I could be treated.
世卫组织现在呼吁，在具有明确界定的条件下并且作为结核病和耐多药结核病治疗控制国家计划的部分内容推出全自动核酸扩增试验。
WHO is now calling for the fully automated NAAT to be rolled out under clearly defined conditions and as part of national plans for TB and MDR-TB care and control.
问：除了钱外，什么是开展耐多药结核病治疗规划的最重要因素？
Q: Aside from money, what has been the most important factor in running a MDR-TB treatment programme?
进一步的检测显示，那些治疗失败的病人患的是耐多药结核病，官员意识到了耐多药结核病的流行。
Further tests revealed those who failed treatment had MDR-TB; officials realized they had an epidemic of these cases.
到2008年底，耐多药结核病项目总共治疗了1316例病人。
By the end of 2008, the MDR-TB project had treated 1316 patients in all.
耐多药结核病是所有国家面临的一个挑战，这是由于该病治疗起来存有难度并且费用昂贵。
MDR-TB is a threat to all countries as it is difficult and expensive to treat.
世界卫生组织(世卫组织)估计，在每年感染耐多药结核病的大约50万人当中，接受治疗的人很少，仅占10%。
The World Health Organization (who) estimates that as few as 10% of the roughly 500,000 people who contract MDR-TB every year receive treatment.
“上世纪八十年代，普遍认为耐多药结核病不可能得到诊断和治疗，”Jaramillo说。
"In the 1980s the common wisdom was that MDR-TB was impossible to diagnose and treat," says Jaramillo.
在马尼拉一家耐多药结核病诊所，我看到48岁的AntiaSilverio在刚刚结束5个月的耐多药结核病治疗后为医生、护士和病人跑腿打下手。
At one MDR-TB clinic in Manila, I watched Antia Silverio, a 48-year-old who had just finished her MDR-TB treatment five months before, run errands for doctors, nurses and patients.
2010年耐多药结核病病人得到治疗的人数上升到了4.6万人，而这仅仅占到需要得到治疗的耐多药结核病病人估计数字的16%。
While the number of MDR-TB patients treated increased to 46 000 in 2010 - this is just 16% of the estimated number of MDR-TB patients that needed treatment.
要在未来五年中使100万人获得耐多药结核病方面的有效治疗，我们就需要与所有合作伙伴一起合作，尤其是受到疾病影响的社区。
To reach a million people with effective care for MDR-TB over the next five years, we will need to work closely with all partners, especially with affected communities.
确保制定一个耐多药/广泛耐药结核病综合管理与治疗框架；
to ensure development of a comprehensive M/XDR-TB management and care framework;
使用一个疗程标准结核病药物的成本约为20美元，而耐多药结核病药物的成本可以高达5000美元，广泛耐药结核病的治疗费用则更加昂贵。
While a course of standard TB drugs cost approximately US$ 20, MDR-TB drugs can cost up to US$ 5 000, and XDR-TB treatment is far more expensive.
世界卫生组织称“耐多药肺结核”的治疗费用比其他肺结核病贵一百多倍。
The World Health Organization says MDR-TB is one hundred times more costly to treat than the other form of the disease.
世界卫生组织称“耐多药肺结核”的治疗费用比其他肺结核病贵一百多倍。
The World Health Organization says MDR-TB is one hundred times more costly to treat than the other form of the disease.
应用推荐